Ticagrelor's pharmacological profile differs from clopidogrel not only in reversibility but also in an additional mechanism that contributes to its mortality benefit in ACS. Ticagrelor:

• A Directly inhibits thromboxane synthase in platelets providing dual TXA2/P2Y12 inhibition unlike clopidogrel
• B Activates prostacyclin (PGI2) receptor on platelets independent of P2Y12 blocking, providing additive antiplatelet synergy
• C Inhibits GP IIb/IIIa receptor crosslinking as an off-target effect during platelet activation
• D Inhibits adenosine reuptake by blocking ENT1 (equilibrative nucleoside transporter 1) in red blood cells, increasing systemic adenosine levels with coronary vasodilatory and ischemic preconditioning effects ✓

Explanation

Ticagrelor and its active metabolite AR-C124910XX inhibit equilibrative nucleoside transporter 1 (ENT1) in erythrocytes and other cells, reducing cellular adenosine uptake and thus raising plasma and tissue adenosine concentrations. This adenosine accumulation contributes to coronary vasodilation, cardioprotection via A1-mediated ischemic preconditioning, and anti-inflammatory effects. This mechanism is also responsible for ticagrelor's characteristic side effects of dyspnea (adenosine in pulmonary tissue) and bradycardia. This off-target adenosine effect may partially explain ticagrelor's mortality reduction beyond pure P2Y12 inhibition observed in PLATO trial.

Reference: KD Tripathi, Essentials of Medical Pharmacology, 8th ed.

High-yield for: NEET PGINI-CETNExTFMGEUSMLEPLABMRCP

Written and medically reviewed by the StethoPrep medical team.